Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Sandoz Group AG's share price for the quarter that ended in Dec. 2023 was $32.01. Sandoz Group AG's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 430 Mil. Therefore, Sandoz Group AG's market cap for the quarter that ended in Dec. 2023 was $13,762 Mil.
Sandoz Group AG's quarterly market cap
stayed the same
from . 20 ($0 Mil) to Dec. 2022 ($0 Mil) but then
increased
from Dec. 2022 ($0 Mil) to Dec. 2023 ($13,762 Mil).
Sandoz Group AG's annual market cap
stayed the same
from . 20 ($0 Mil) to Dec. 2022 ($0 Mil) but then
increased
from Dec. 2022 ($0 Mil) to Dec. 2023 ($13,762 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Sandoz Group AG's Enterprise Value for Today is $18,578 Mil.
Sandoz Group AG Market Cap Historical Data
The historical data trend for Sandoz Group AG's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Sandoz Group AG Market Cap Chart
Sandoz Group AG Annual Data
Trend
Dec22
Dec23
Market Cap
-
13,762.03
Sandoz Group AG Quarterly Data
Dec22
Dec23
Market Cap
-
13,762.03
Competitive Comparison of Sandoz Group AG's Market Cap
For the Drug Manufacturers - Specialty & Generic subindustry, Sandoz Group AG's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sandoz Group AG's Market Cap Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sandoz Group AG's Market Cap distribution charts can be found below:
* The bar in red indicates where Sandoz Group AG's Market Cap falls into.
Sandoz Group AG Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Sandoz Group AG's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sandoz Group AG (OTCPK:SDZNY) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Sandoz Group AG Market Cap Related Terms
Thank you for viewing the detailed overview of Sandoz Group AG's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Sandoz Group AG (Sandoz Group AG) Business Description
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as U.S.'s first biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in pipeline.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SDZNY has been successfully added to your